Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06177171 · ClinicalTrials.gov registry record · Phase 1
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
A Phase 1 study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Pamela Munster.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06177171 is a Phase 1 study of BRCA1 Mutation and BRCA2 Mutation that is actively recruiting participants, run by Pamela Munster. The registered enrollment target is 18 participants, below the 576-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06177171, a Phase 1 study of BRCA1 Mutation and BRCA2 Mutation, is actively recruiting participants, sponsored by Pamela Munster.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2 (CHEK2) mutations).
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG ASTX727
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06177171
The ClinicalTrials.gov registry entry for NCT06177171 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 576-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (97% lower). The listed sponsor is Pamela Munster, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT06177171 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06177171 about?
NCT06177171 is a clinical study titled "Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors". This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhi...
What is the current status of trial NCT06177171?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-02-07. Estimated completion is 2028-01-31.
What conditions does trial NCT06177171 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, BRCA Mutation, PALB2 Gene Mutation.
What interventions are being tested in trial NCT06177171?
The interventions under investigation include: Olaparib (DRUG), ASTX727 (DRUG).
Who is sponsoring clinical trial NCT06177171?
This trial is sponsored by Pamela Munster, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06177171 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
RECRUITING · Phase 1
-
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
COMPLETED · Phase 1
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.